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Background: The beneficial effects of curcumin which includes its antioxidant, anti-inflammatory and cancer
chemo-preventive properties have been identified. Little information is available regarding the optimal dose and
treatment periods of curcumin on the proliferation rate of different sources of stem cells.
Methods: In this study, the effect of various concentrations of curcumin on the survival and proliferation of two types
of outstanding stem cells which includes bone marrow stem cells (BMSCs) and adult rat neural stem/progenitor cells
(NS/PCs) at different time points was investigated. BMSCs were isolated from bilateral femora and tibias of adult Wistar
rats. NS/PCs were obtained from subventricular zone of adult Wistar rat brain. The curcumin (0.1, 0.5, 1, 5 and 10 μM/L)
was added into a culture medium for 48 or 72 h. Fluorescent density of 5-bromo-2′-deoxyuridine (Brdu)-positive cells
was considered as proliferation index. In addition, cell viability was assessed by MTT assay.
Results: Treatment of BMSCs with curcumin after 48 h, increased cell survival and proliferation in a dose-dependent
manner. However, it had no effect on NSCs proliferation except a toxic effect in the concentration of 10 μM of curcumin.
After a 72 h treatment period, BMSCs and NS/PCs survived and proliferated with low doses of curcumin. However, high
doses of curcumin administered for 72 h showed toxic effects on both stem cells.
Conclusions: These findings suggest that curcumin survival and proliferative effects depend on its concentration,
treatment period and the type of stem cells. Appropriate application of these results may be helpful in the outcome of
combination therapy of stem cells and curcumin.
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Curcumin (diferuloylmethane) is one of the active compo-
nents of dietary spice turmeric (Curcuma longa Linn) which
was first chemically characterized in 1910 [1, 2]. To date, a
great number of studies have focused on the multifarious
biological effects of curcumin including its antioxidant,
anti-inflammatory and cancer chemo-preventive properties
[3, 4]. In addition, some papers have reported that curcumin
can decrease oxidative damage and improve cognitive defi-
ciencies related to aging. Moreover, curcumin can also be* Correspondence: hassanzadeh@tums.ac.ir
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creativecommons.org/publicdomain/zero/1.0/useful for the treatment of neurodegenerative diseases such
as Alzheimer’s disease and brain ischemia [5, 6]. Further-
more, there are some reports on the synergistic effect of
curcumin in conjunction with stem cell therapy vis-à-vis re-
covery from spinal cord injury [7]. In this regard, curcumin
may enhance proliferation of stem cells for swift regener-
ation [7, 8]. Previous investigations have reported that cur-
cumin has biphasic effects on the proliferation of some
stem cells including spinal cord neural progenitor cells [9],
embryonic neural progenitor cells [8] and 3 T3-L1 preadi-
pocytes [10]. To find the optimal curcumin concentration
as well as the administration time for treatment of different
types of stem cells with curcumin, more studies are needed.
Among different sources of stem cells, bone marrow
mesenchymal stem cells (BMSCs) are known to haveicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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chymal and non-mesenchymal lineages. In many previ-
ous study, these types of stem cells were used for cell
and gene therapy due to their capacity for self-renewal
in a number of non-hematopoietic tissues as well as
their multi-potentiality for differentiation [11].
On the other hand, adult neural stem/progenitor cells
(NS/PCs) are self-renewal and multi-potent cells located
specially in the subventricular zone of the lateral wall of
the lateral ventricle of an adult mammalian brain. These
cells can be isolated and cultured in-vitro to produce true
neural and glial cells and finally transplanted for the treat-
ment of neurodegenerative diseases [12, 13]. Little is
known about the effective dose and treatment periods of
curcumin when it is utilized as a supportive element for
BMSCs and NS/PCs. Hence, in this study, the effects of
various concentrations of curcumin on survival and prolif-




BMSCs were extracted from the bone marrow of bilateral
femora and tibias of 4 weeks old male Wistar rats. The cell
suspension was centrifuged and plated on T-25 plastic
flasks in Dulbecco’s Modified Eagle Medium (DMEM/F12)
(Invitrogen, USA), supplemented with 10 % fetal bovine
serum (FBS, Invitrogen, USA), 100U/ml penicillin and
100 mg/ml streptomycin (Invitrogen, USA) and incubated
at 37 °C with 5 % CO2. When primary cultures became al-
most confluent, the cells were passaged by trypsinization
and cultured in the above compound. All of the experi-
ments were performed using cells at passages 10-18 [14].
NS/PCs culture
SVZ specimens were harvested from the brain of young
adult male Wistar rats (150-200 g) and transported in 10 %
penicillin-streptomycin solution (prepared with 0.1 M cold
PBS, PH 7.2-7.4). Next, 500 μl of 0.05 % trypsin/ EDTA so-
lution (Invitrogen, USA, 5 min at 37 °C) was used for tissue
dissection. The reaction was brought to a halt by the
addition of 500 μl of Soybean trypsin inhibitor (Sigma,
USA) to the dissociated tissue. After centrifugation, the
cells were placed on T-25 plastic flasks in 5 mL of DMEM/
F12 containing 1 % N2 supplement (Invitrogen, USA), 3 %
B27 supplement (Invitrogen, USA), 2 μg/mL heparin
(Sigma, USA), 1 % glutamax (Invitrogen, USA), 1 % penicil-
lin/streptomycin (Invitrogen, USA), 10 ng/ml basic fibro-
blast growth factor (bFGF; Millipore, Germany), 20 ng/ml
epidermal growth factor (EGF; Miltenybiotech, Germany),
at 37 °C in a humidified atmosphere with 5 % CO2. Neuro-
spheres were passaged by trypsinization and mechanically
separated after 15 days [12, 15]. The NS/PCs obtained from
the third passage were used for all experiments.Cell viability assay
Cell viability was assessed by MTT (3-(4,5-dimethylthiazo-
lyl-2) -2,5-diphenyltetrazolium bromide) assay. NS/PCs
and BMSCs were seeded at a density of 1×104 cells in 96-
well plates. Curcumin (Sigma, USA) was dissolved in Di-
methyl Sulphoxide (DMSO) (Sigma, USA) and added in
different concentrations of 0.1, 0.5, 1, 5 and 10 μM/L into
the culture medium. In the control group, cells were
treated with the DMSO. Forty-eight and seventy two
hours after the treatment, the medium containing curcu-
min was replaced with fresh medium containing 1 mg/ml
MTT solution in 0.01 M PBS. The plates were incubated
at a temperature of 37 °C for 4 h. The mitochondrial de-
hydrogenase of viable cells broke down MTT and pro-
duced purple formazan. The cells were disrupted in
DMSO. The purple formazan dye was then measured with
ELISA reader at 595 nm absorbance [16]. Each experi-
ment was repeated three times.
Immunofluorescent assay
The cells were fixed with 4 % paraformaldehyde in PBS
for 1 h then rinsed with PBS three times for 5 min and in-
cubated with blocker solution (5 % normal goat serum
and 1 % bovine serum albumin in PBS) for 60 min. Mouse
anti-Nestin (1:100; Abcam, USA) [12], rabbit anti-CD73
(1:200; Abcam, USA) or rabbit anti-CD105 (1:100; Abcam,
USA) [17] were used at 4 °C over night. After washing
with PBS, goat anti-Mouse IgG (alexa flour 647, 1:600;
invitrogen, USA) or goat anti-Rabbit IgG (FITC; 1:700;
Abcam, USA) were added to the cells for 60 min at room
temperature and the nuclei were stained with 4,6-diami-
dino-2-phenylindole (DAPI, 1 g/ml, Santa Cruz, Germany)
or Propidium Iodide (PI; invitrogen, USA). Immuno-
labeled cells were assessed by a fluorescent microscope
(Olympus, japan). In control samples, the primary anti-
bodies were eliminated in a reaction in which no immuno-
reactivity was detected.
Bromodeoxyuridine (BrdU) Immunocytochemistry
Cells were plated onto polyornithine (50 μg/ml) coated
96-well plates at a density of 1×104 cells. Cells were
treated with either DMSO or curcumin at two time
points (48 and 72 h). Adherent cells and neurospheres
were then fixed in 4 % paraformaldehyde for 30 min.
The cells were washed with 0.2 % Triton-X 100 in 0.1 M
PBS (pH 7.4) three times for 5 min. DNA was denatured
by exposing the cells to acid (2 M HCl, 30 min at 37 °C).
After that, borate buffer (0.1 M) was added to the cells
for 12 min at room temperature. Then, 5 % normal goat
serum in 0.1 M PBS (pH 7.4) was added to block en-
dogenous peroxidases. Next, the cells were incubated
overnight with mouse anti-BrdU antibody (1:1000,
Sigma, Germany) and thereafter exposed to FITC conju-
gate anti-mouse IgG (1:1000, Sigma, Germany) for BMSCs
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Abcam USA) for NS/PCs for 2 h at room temperature.
Each experiment was repeated three times.
Proliferating cells and neurospheres were incubated by
10 μM/l BrdU for 48 h and analyzed by immuno-staining
[18]. Fluorescent density of Brdu positive cells were mea-
sured using image J software [19, 20]. The study had the
endorsement of the ethical committee of Tehran Univer-
sity of Medical Sciences.
Statistical analysis
The statistical significance was determined using the t-test
and One-Way Analysis of Variance (ANOVA) and a
Tukey post-hoc test. The results are expressed as mean ±
SEM. The null hypothesis was rejected at the 0.05 level of
significance.
Results
Isolation of BMSCs and NS/PCs
After primary culture, BMSCs were obtained as mono-
layer cells which expressed mesenchymal stem cell
markers CD105 and CD73. Cultivation of SVZ specimen
resulted in the production of neurospheres which
expressed nestin as a marker of NS/PCs (Fig. 1).
Effect of curcumin on proliferation of BMSCs
As indicated in Fig. 2, in the aftermath of 48 h adminis-
tration, curcumin enhanced the BrdU positive BMSCs in
a dose dependent manner, suchthat the doses of 5 and
10 μM of curcumin enhancement was statistically sig-
nificant compared to the DMSO group (P < 0.01).
After 72 h treatment with different doses of curcumin,
the above pattern was not seen, only the concentration of
0.5 μM of curcumin could considerably increase the BrdU
positive BMSCs compared to the DMSO group (P < 0.001).Fig. 1 Primary culture of NS/PCs and BMSCs. NS/PCs were cultured as floutin
stem cell marker nestin (c). BMSCs were cultured as adherent cells (d) which eEffect of curcumin on proliferation of NS/PCs
There were no significant differences among the groups
after 48 h treatment of NS/PCs with various doses of cur-
cumin except for the 10 μM curcumin group in which the
fluorescent density of BrdU was significantly decreased
compared to the DMSO group (P < 0.05, Fig. 3).
After 72 h administration of curcumin, there was an in-
crease in BrdU positive NS/PCs in doses of 0.1, 0.5 (P <
0.01) and 1 μM (P < 0.001) of curcumin compared to the
DMSO group. The proliferation rate of NS/PCs signifi-
cantly decreased following the administration of 5 or
10 μM of curcumin when compared with that of the
DMSO group (P < 0.05, Fig. 3).Effect of curcumin on survival of BMSCs
The results of MTT assay showed that all concentra-
tions of curcumin including 0.1, 0.5, 1 (P < 0.05), 5 and
10 μM (P < 0.01) could enhance the viability of BMSCs
after 48 h compared to the DMSO group (Fig. 4). Fol-
lowing 72 h treatment, the survival of BMSCs signifi-
cantly increased with 0.5 μM of curcumin (P < 0.001),
but this index considerably decreased with 5 and 10 μM
of curcumin (P < 0.05) compared to the DMSO group.Effect of curcumin on survival of NS/PCs
According to the results of MTT assay, curcumin with
concentrations of 5 and 10 μM significantly reduced via-
bility of NS/PCs compared to the DMSO group after 48 h
(Fig. 5, P < 0.05). Moreover, following 72 h of NS/PCs en-
counter with curcumin, the highest cell viability was seen
by using 1 μM of curcumin (P < 0.001 compared to the
DMSO group). However, high doses of curcumin (5 and
10 μM) considerably decreased the viability of NS/PCs in
comparison with the DMSO group (P < 0.05).g neurospheres (a) or slightly adherent cells (b) which expressed neural
xpressed mesenchymal stem cell markers CD105 (e) and CD73 (f)
Fig. 2 The effect of various concentrations of curcumin on proliferation of BMSCs after 48 and 72 h. Different doses of curcumin (0.1, 0.5, 1, 5 and
10 μM) added 48 or 72 h into culture medium have various proliferative effects on BMSCs . The above pictures indicate the BrdU positive cells (green)
in the DMSO 48 h group (a), 10 μM curcumin 48 h group (b), DMSO 72 h group (c) and 0.5 μM curcumin 72 h group (d). Scale bare:40 μm. e,
fluorcent density for BrdU positive cells in different doses of curcumin after 48 or 72h, **: P < 0.01 or ***: P < 0.001 vs the DMSO group
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In the present study we observed multifarious effects of
curcumin in terms of cell viability and stem cell prolifer-
ation. After administration of different doses of curcu-
min (0.1, 0.5, 1, 5 and 10 μM/L) to BMSCs, the high
doses of curcumin enhanced the proliferation of BMSCs
after 48 h However, when these cells were exposed to
curcumin for 72 h, the increase in cell proliferation was
seen only in doses of 0.5 μM of curcumin. On the other
hand, the high doses of curcumin had adverse effects on
the proliferation of NS/PCs while the doses of 0.1, 0.5
and 1 μM/L of curcumin administered for 72 h had
beneficial effects on proliferation. The effect of curcumin
on viability of BMSCs and NS/PCs was almost similar to
its effect on proliferation of the cells.Previous studies evaluated some of the effects of cur-
cumin on the proliferation and viability of the cells. Kim
et al. [8] revealed that after a 24 h treatment period, low
concentration (0.5 μM) of curcumin was the most effect-
ive dose for increasing Brdu positive cells and cell viabil-
ity of NS/PCs in cell culture. They opined that the
stimulatory mechanism of low doses of curcumin on
neural stem cells was facilitated by ERK and p38 MAP
kinases [8]. In addition, Kim et al.[10] reported an in-
crease in cell proliferation of preadipocytes with low
concentrations of curcumin during a 24 h treatment
period [10]. Moreover, Ormand et al. [7] reported that
after 24 h, low doses of (0.5 μM) curcumin was the most
effective concentration for increasing the neurosphere
diameter of NS/PCs isolated from the adult rat SVZ, as
Fig. 3 The effect of various concentrations of curcumin on proliferation of NS/PCs after 48 and 72 h. Proliferation of NSCs was evaluated using fluorescent
density for Brdu-positive cells. This index was different in the groups following 48 or 72 h treatment of NS/PCs with curcumin. The above photographs
show the BrdU positive cells (red) in the DMSO 48 h group (a), 10 μM curcumin 48 h group (b), DMSO 72 h group (c) and 1 μM curcumin 72 h group (d).
Scale bare:24 μm. e, fluorcent density for BrdU positive cells in different doses of curcumin after 48 or 72h, *: P< 0.05, **: P< 0.01 or ***: P< 0.001 vs the
DMSO group
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that curcumin can be utilized at low doses to induce
heme oxygenase 1 at pharmacological levels, and its in-
duction is accompanied by generation of non-lethal
levels of reactive oxygen species [3]. On the other hand,
Kim et al. [8] reported a cytotoxic effect with concentra-
tions more than 10 μM of curcumin [8]. Ormand et al.
[7] also demonstrated that curcumin at higher doses
caused apoptosis [7]. Another report showed that the
concentrations of 1-50 μM of curcumin increased cell
viability while doses higher than 80 μM decreased it
[16]. The discrepancies observed among the studies may
be attributed in part to the different species, duration of
curcumin exposure and the dose of curcumin. In the
present study, the different doses of curcumin andtreatment duration were chosen based on a pilot study as
well as previous reports [10, 8]. It is important to point out
that according to the results of the present study; it seems
that the toxic effects of curcumin on NS/PCs were more
sensitive than that on BMSCs.
Indeed, in the light of latest investigations and results,
curcumin acts as a double-edged sword. In other words, it
can be toxic to cells and can also be helpful. It depends on
the dose and type of cells. Based on this fact, curcumin
should be used cautiously in future treatment strategies.
Recent studies have shown that curcumin could reduce oxi-
dative damage related to aging and was beneficial in the
treatment of neurodegenerative diseases such as Alzheimer
diseases, Parkinson disease, and stroke in animal models
[21–25]. Xu et al. [26] showed that curcumin could reverse
Fig. 4 The effect of various concentrations of curcumin on viability of BMSCs after 48 and 72 h. Cell viability of BMSCs was assessed using MTT
assay method. The results indicated that dose and exposure time of curcumin were the factors infuence the cell viability. *: P < 0.05, **: P < 0.01
or ***: P < 0.001 vs the DMSO group
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by chronic stress. Their results suggested that curcumin
could increase the cell proliferation and neuronal popula-
tions in stress-induced behavioral abnormalities and hip-
pocampal neuronal damage. Moreover, curcumin effects
were induced by up-regulation of 5-HT1A receptors and
BDNF [26]. Fadhel et al. [24] indicated that administration
of 200 mg/kg of curcumin by intraperitoneal method im-
mediately, 3 h and 24 h after transient forebrain, ischemiaFig. 5 The effect of various concentrations of curcumin on viability of NS/P
on survival of NS/PCs. In addition, the cell viabilty was affected by period omodel significantly reduced neuronal damage. This pro-
tective effect did not differ among these three different
times. Fusheng et al. [21] reported that five months ad-
ministration of 500 ppm curcumin in aged APP transgenic
mice suppressed amyloid accumulation. Kim et al. showed
that when curcumin was administered intraperitoneally at
a dose of 500 nmol/kg body weight of adult mice once
daily for 4 days, the Numbers of Newly Generated Cells in
the Hippocampus increased [8]. However, the translationCs after 48 and 72 h. Curcumin in different doses had various effects
f treatment. *: P < 0.05 or ***: P < 0.001 vs the DMSO group
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job. The results of phase I clinical trials indicated that cur-
cumin is safe even at high doses (12 g/day). Humans how-
ever exhibit poor bioavailability [27]. Considering the fact
that curcumin in the face of stem cells exhibits a biphasic
effect, further investigation is needed to determine specific
effects of curcumin on different types of stem cells.
Conclusion
These findings suggest that curcumin proliferation effects
depend on treatment period, its concentration, and the type
of stem cells. These factors should be considered in stem
cell therapy of degenerative and neurological disorders. Fur-
ther studies are required to evaluate the synergistic effect of
combination therapy of curcumin and stem cells.
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